-
1دورية أكاديمية
المؤلفون: Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., Holovanchuk, D., Pedersen, M., McLeary, R., Lorigan, P., Dhomen, N., Fisher, C., Banerji, U., Dean, E., Krebs, M. G., Gore, M., Larkin, J., Marais, R., Springer, C.
المساهمون: Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., Holovanchuk, D., Pedersen, M., Mcleary, R., Lorigan, P., Dhomen, N., Fisher, C., Banerji, U., Dean, E., Krebs, M. G., Gore, M., Larkin, J., Marais, R., Springer, C.
مصطلحات موضوعية: CRC, KRAS, NSCLC, panRAF/SRC inhibitor, PDAC
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33130216; info:eu-repo/semantics/altIdentifier/wos/WOS:000608030000017; volume:32; issue:2; firstpage:269; lastpage:278; numberofpages:10; journal:ANNALS OF ONCOLOGY; http://hdl.handle.net/11380/1215608Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85098875008
-
2دورية أكاديمية
المؤلفون: Saturno, G, Lopes, F, Niculescu-Duvaz, I, Niculescu-Duvaz, D, Zambon, A, Davies, L, Johnson, L, Preece, N, Lee, R, Viros, A, Holovanchuk, D, Pedersen, M, McLeary, R, Lorigan, P, Dhomen, N, Fisher, C, Banerji, U, Dean, E, Krebs, MG, Gore, M, Larkin, J, Marais, R, Springer, C
المساهمون: Banerji, Udai
وصف الملف: Print-Electronic; 278; application/pdf
العلاقة: Annals of oncology : official journal of the European Society for Medical Oncology, 2021, 32 (2), pp. 269 - 278; https://repository.icr.ac.uk/handle/internal/4228Test
الإتاحة: https://doi.org/10.1016/j.annonc.2020.10.483Test
https://repository.icr.ac.uk/handle/internal/4228Test -
3دورية أكاديمية
المؤلفون: Dean, Emma, Banerji, U, Girotti, Romina, Niculescu-Duvaz, I, Lopes, F, Davies, L, Niculescu-Duvaz, D, Dhomen, N, Ellis, S, Ali, Z, O'Carrigan, B, Carter, L, Chisolm, L, Dive, Caroline, Lane, HA, Lorigan, Paul, Gore, ME, Larkin, J, Marais, Richard, Springer, C
المصدر: Dean , E , Banerji , U , Girotti , R , Niculescu-Duvaz , I , Lopes , F , Davies , L , Niculescu-Duvaz , D , Dhomen , N , Ellis , S , Ali , Z , O'Carrigan , B , Carter , L , Chisolm , L , Dive , C , Lane , HA , Lorigan , P , Gore , ME , Larkin , J , Marais , R & Springer , C 2016 , A Phase 1 first-in-human trial to evaluate the safety and tolerability of CCT3833, an oral panRAF inhibitor, in ....
-
4كتاب
المؤلفون: Niculescu-Duvaz, I., Simon, Z., Voiculetz, N.
المصدر: Chemistry and Biology of Synthetic Retinoids ; page 575-606 ; ISBN 9781351070638
-
5دورية أكاديمية
المؤلفون: Niculescu-Duvaz, I., D'mello, L., Maan, Z., Barron, J.L., Newman, D.J., Dockrell, M.E.C., Kwan, J.T.C.
المصدر: Kidney International ; volume 69, issue 7, page 1272-1275 ; ISSN 0085-2538
مصطلحات موضوعية: Nephrology
الإتاحة: https://doi.org/10.1038/sj.ki.5000240Test
https://api.elsevier.com/content/article/PII:S0085253815516463?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0085253815516463?httpAccept=text/plainTest -
6دورية أكاديميةTrastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+metastatic breast cancer
المؤلفون: Niculescu-Duvaz, I
المساهمون: Niculescu-Duvaz, Dan
مصطلحات موضوعية: PHASE-I PHARMACOKINETICS EFFICACY SAFETY RESISTANCE HERCEPTIN MYLOTARG LEUKEMIA ADC MBC
وصف الملف: 360
العلاقة: http://publications.icr.ac.uk/9659Test/; CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2010, 12 (3), pp. 350 - 360; https://repository.icr.ac.uk/handle/internal/1937Test
-
7دورية أكاديمية
المؤلفون: Niculescu-Duvaz, I
المساهمون: Niculescu-Duvaz, Dan
وصف الملف: 566
العلاقة: http://publications.icr.ac.uk/1873Test/; CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2004, 6 (5), pp. 559 - 566; https://repository.icr.ac.uk/handle/internal/1915Test
-
8مؤتمر
المؤلفون: Niculescu Duvaz, I., Menard, D, Niculescu Duvaz, D., Davies, L, Preece, N., Kirk, R., Whittaker, S., Marais, R., Springer, C., ZAMBON, Alfonso
المساهمون: Niculescu Duvaz, I., Menard, D, Niculescu Duvaz, D., Zambon, Alfonso, Davies, L, Preece, N., Kirk, R., Whittaker, S., Marais, R., Springer, C.
العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000288460100435; firstpage:139; lastpage:139; journal:EUROPEAN JOURNAL OF CANCER; http://hdl.handle.net/11380/1138752Test
الإتاحة: https://doi.org/10.1016/S1359-6349Test(10)72148-0
http://hdl.handle.net/11380/1138752Test -
9دورية أكاديمية
المؤلفون: Saturno, G., Lopes, F., Girotti, M.R., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Viros, A., Pedersen, M., McLeary, R., Knight, R., Lee, R., Holovanchuk, D., Fusi, A., Lorigan, P., Dhomen, N., Marais, R., Springer, C.
المصدر: Saturno , G , Lopes , F , Girotti , M R , Niculescu-Duvaz , I , Niculescu-Duvaz , D , Zambon , A , Davies , L , Johnson , L , Preece , N , Viros , A , Pedersen , M , McLeary , R , Knight , R , Lee , R , Holovanchuk , D , Fusi , A , Lorigan , P , Dhomen , N , Marais , R & Springer , C 2016 , ' Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models ' , ....
الإتاحة: https://doi.org/10.1016/s0959-8049Test(16)61703-3
https://research.manchester.ac.uk/en/publications/8f457493-f171-4ba2-a527-7b62836cc9acTest
http://www.mendeley.com/research/therapeutic-efficacy-paradoxbreaking-panraf-src-drug-cct3833bal3833-krasdriven-cancer-modelsTest -
10دورية أكاديمية
المؤلفون: Mafham, M, Niculescu-Duvaz, I, Barron, J, Emberson, JR, Dockrell, M, Landray, M, Baigent, C
العلاقة: https://ora.ox.ac.uk/objects/uuid:2fe89cf1-75ae-4085-b751-682609f3bfdeTest; https://doi.org/10.1159/000102997Test
الإتاحة: https://doi.org/10.1159/000102997Test
https://ora.ox.ac.uk/objects/uuid:2fe89cf1-75ae-4085-b751-682609f3bfdeTest
النص الكامل